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In the sorbitol pathway, two enzymes catalyze the conversion of free glucose to its sugar alcohol, sorbitol, and the further conversion of sorbitol to fructose. characterized by a high Km for glucose and galactose. In diabetes and galactosemia, the availability of a large pool of free intracellular aldoses causes an increase in activity of the sorbitol pathway. Aldose reductase requires NADPH as a cofactor, which is provided primarily through the activity of the hexosemonophosphate shunt. A nearly stoichiometric relationship between the hexosemonophosphate shunt activity (NADPH production) and sorbitol formation has been demonstrated for lens (1) and nerve (2) . Recent studies indicate an important role for the sorbitol pathway in the etiology of diabetic and galactosemic cataract formation (3), neuropathy (4, 5) , and tubular nephropathy (6) . The sorbitol pathway is present in the pancreas. Aldose reductase has recently been isolated and purified from beef (7) , rabbit (8) , and human pancreas (unpublished observation). We have recently localized aldose reductase by immunological methods to the islets of Langerhans (manuscript in preparation). Morrison et al. (9) have described the presence of sorbitol and free fructose in isolated rat pancreatic islets in concentrations exceeding those found in plasma or acinar Abbreviation: Glt, glutaric acid.
tissues. Whole pancreas also contains NADP-L-hexonate dehydrogenase (L-gulonate: NADP oxidoreductase, EC 1.1.1. 19) , an enzyme of the glucuronic acid-xylulose shunt with ability to reduce many uronic acids, but with poor affinity for aldoses.
Extensive studies of glucose-induced release of insulin in the islets of Langerhans have thus far failed to indicate the nature of the signal or the metabolic pathway(s) involved. If anything, the constancy of the metabolite concentrations in the islets, in the glycolytic and the hexosemonophosphate pathways during glucose-stimulated release of insulin, is remarkable (10) . It is now well established that the beta cell is freely permeable to glucose, and that the intracellular glucose concentration increases very rapidly in response to increased extracellular concentrations (greater than 6-fold in 0.5 min) (10) .
Furthermore, a number of investigators have shown that NADPH is necessary for glucose-mediated release of insulin. Electron acceptors (11) and 6-aminonicotinamide (12) , agents that are known to interfere with the availability or formation of NADPH, inhibit the glucose-induced release of insulin.
The kinetic characteristics of aldose reductase, the availability of a large pool of free intracellular glucose, and the NADPH requirement for insulin release suggested that the sorbitol pathway may be ideally suited to act as a signal for glucose-induced release of insulin.
The availability of inhibitors of aldose reductase (13) Moore and McGregor (14) at a flow rate of 20 ml/hr. 6-ml fractions were collected and assayed for protein and enzyme activity as described (4 In experiments with aldose reductase inhibitors, glutaric acid (Glt), 2,4-dimethyl glutaric acid [(CH3)2Glt], and (CH2)4Glt were neutralized with sodium hydroxide and added to the medium to produce the desired concentration. In both control and inhibitor experiments, the perfusion fluid was recirculated through the pancreas for an exact period of 30 min, during which time the flow rate was adjusted and the preparation was exposed to the particular compound.
At the end of the recirculation period, glucose was infused into the arterial side with a Harvard syringe pump to produce the desired effluent concentration (300 mg of glucose per 100 ml) and samples were taken at 30-sec intervals. Tolbutamide was infused to produce a concentration of about 45 mg per 100 ml of effluent.
Insulin concentrations in the samples were measured in duplicate by the double antibody immunoassay technique (17) 
RESULTS

Enzyme purification
Two main reducing activities were eluted on DEAE-cellulose chromatography of whole pancreas extract (Fig. 1) . The first enzyme peak eluted in the buffer wash and contained considerable activity with glucuronate as a substrate. The ratio of the glucuronate-reducing activity to glyceraldehydereducing activity was 6: 1. The elution pattern and substrate specificities of this enzyme peak indicated that the enzyme of hexonate dehydrogenase in the pancreas is not known, and since (CH2)4Glt, Glt, and colchicine inhibited both enzymes, the dichotomy of the inhibitory potency of (CH3)2-Glt on hexonate dehydrogenase and aldose reductase was especially useful in determination of the specificity of action of these compounds in the perfused rat pancreas.
Effect of (CH2)4Glt, Glt, and (CH3)2Glt on insulin release (Figs. 2 and 3, and Table 3 ) Fig. 2 shows that first phase release of insulin in response to glucose stimulation began 90 sec after the start of the glucose pulse, reached a peak at-120 sec, and declined to the lowest value by 5 min; this was followed by a gradually rising rate of insulin secretion (second phase) up to 10 min of glucose stimulation. Glucose pulse shutoff led to decreasing insulin output beginning at 150 sec and reaching prestimulatory insulin levels 3 min after shutoff. The subsequent response to tolbutamide infusion consistently reached a peak at 60 sec with subsequent decline to baseline levels at 3 min.
Pancreases treated with increasing concentrations of (CH2)4Glt showed progressive inhibition of glucose-induced insulin response (pattern not shown). At 10 mM of (CH2)4-Glt, insulin response was reduced by 50% (Table 3) . At 15 and 20 mM (CH2)4Glt, the insulin response was markedly attenuated, although a small delayed and broadened response was still seen. There were no differences in the patterns or amounts of insulin secretion between the control pancreases and those treated with 5 mM Glt or 5 mM (CH3)2Glt (Table   3) . Fig. 2 also shows the results obtained by use of 7.5 mM of each of Glt and (CH3)2Glt. Insulin release by pancreatic preparations exposed to 7.5 mM (CHB)2Glt was normal with no diminution or alteration in pattern. However, 7.5 mM Glt [a more potent inhibitor of rat aldose reductase than (CH8)2Glt] showed a significant inhibition of first phase insulin release and a decrease (flattening of the curve) of second phase insulin secretion. The tolbutamide-induced insulin release by the 7.5 mM Glt-treated preparations, though diminished, was not significantly different from the insulin release by control preparations. Fig. 3 shows the effects of 10 mM Glt and 10 mM (CH3)2Glt on insulin secretion. At these concentrations, an inhibitory effect on rates of first phase and second phase insulin release was noted with both compounds, although Glt showed greater inhibition. In both instances, second phase insulin-release response was practically absent. Tolbutamide-induced insulin release was significantly decreased (41%, P < 0.05) in pancreases treated with 10 mM (CH3)2Glt, and even further depressed with 10 mM Glt (65%, P < 0.001). The addition of sorbitol (300 mg/100 ml) during the 30-min recirculation period to pancreases treated with 10 mM Glt restored the ability of the pancreases to respond to glucose stimulation (Fig. 3) . Both phases of insulin release, as well as subsequent tolbutamide response, were restored to normal. Sorbitol by itself did not stimulate the release of insulin.
Effect of colchicine on release of insulin (Fig. 4 and Table 3 ) Fig. 4 demonstrates the effect on insulin release of colchicine perfusion for 30 min before stimulation with glucose. The data show that increasing concentrations of colchicine progressively inhibited both the first phase and second phase of insulin secretion as compared to the control perfusions. Additionally, at concentrations of 2 and 3 mM colchicine, there was a delay in reaching the peak of glucose-induced insulin secretory rates to 3.5 mmi as opposed to the normal 2 min. Second phase insulin release was practically eliminated by treatment with 3 mM colchicine. Tolbutamideinduced insulin release was not depressed.
DISCUSSION
Glucose-induced insulin release is a biphasic process, while tolbutamide induces only a single insulin secretory phase. The biphasic insulin response to glucose was described in studies with the perfused rat pancreas (15), in dog (22), and man (23) . Our data show that the peak insulin response to tolbutamide consistently occurs a full 60 sec earlier than the peak response to glucose, suggesting that tolbutamide exerts its action at a later step in the stimulatory pathway than glucose itself. Further experiments in this laboratory (in preparation) indicate that the superimposition of a glucose infusion (300 mg/100 ml) on a tolbutamide infusion in progress (45 mg/ml) fails to induce additional insulin release. The opposite is also true; the superimposition of a tolbutamide pulse on a maximal glucose infusion also fails to produce significant additional insulin release. These findings support the concept that both glucose and tolbutamide share a final common step in the pathway for insulin release. (11, 12) and aldose reductase for NADPH additionally supports this concept. Since NADPH in islets is provided mainly through the metabolism of glucose-6--phosphate via the hexosemonophosphate shunt, interference with glucose phosphorylation, not surprisingly, also leads to inhibition of glucose-induced insulin release. The findings of Renold and coworkers (25) that inhibition of glucose phosphorylation by mannoheptulose or 2-deoxyglucose paradoxically potentiates tolbutamide-induced insulin release, despite blocking glucose-induced release, may be explained by shunting of glucose into sorbitol formation. Our finding that higher concentrations of Glt and (CH3)2Glt depress tolbutamide-induced release as well is consistent with the idea that sorbitol is required to "prime" or activate an element in the insulin release mechanism of the beta cell. This view is supported by our finding that simultaneous exposure of the pancreas to both Glt (10 mM) and sorbitol (300 mg/100 ml) restored insulin responses to normal (Fig. 3) . Preliminary experiments indicate that galactitol is not as effective as sorbitol in restoring insulin responses. One possible mechanism for such an effect of sorbitol is that it directly interacts with and activates a protein in the beta cell (e.g., microfilaments). Sorbitol has been shown to specifically and stoichiometrically induce an irreversible conformational change in lens alpha crystallin (26) .
The above interpretation is dependent on the specificities of action of the aldose reductase inhibitors used in this study.
With the exception of (CH2)4Glt, there is a good correlation between in vitro inhibitory potency on aldose reductase by Glt, (CH3)2Glt, and colchicine, and their ability to inhibit the release of insulin. The effectiveness of these inhibitors obviously depends on their penetration into the islets during the recirculation period (30 min) before the infusion of glucose. Increasing the period of exposure to 90 min with 1 mM colchicine caused complete inhibition of both phases of insulin release. The poor penetrability of (CH2)4Glt into tissues is supported by data obtained in lenses incubated in media with high concentrations of galactose that showed that the presence of the tetramethylene ring structure in (CH2)4Glt limits its ability to penetrate cell membranes (20) . Glt and (CH3)2Glt do not possess this ring structure and presumably would penetrate the cell membrane more freely. 10 mM of (CH2)4Glt has been shown to block sugar alcohol formation in lenses (27) and sciatic nerves (2) 
